Arthritis refers to a collection of diseases that affect the joints, causing pain and stiffness. There are more than one hundred types of arthritis which can be broadly categorised as either inflammatory or non-inflammatory.
Featured Learning Zones
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Non-inflammatory arthritis includes osteoarthritis, the most common form of arthritis. Osteoarthritis involves degeneration of the articular cartilage that protects the ends of the bones and is a leading cause of disability around the world.
Inflammatory arthritis may arise as the result of an autoimmune or autoinflammatory response. Examples include rheumatoid arthritis and spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis.
There is no known cure for arthritis, so current treatment strategies focus on providing effective palliation and slowing disease progression. Treatment may vary considerably depending upon type and severity.
To find out more about osteoarthritis, visit our dedicated Learning Zone, which contains further information on the treatment strategies, medications and relevant guidelines that are available to facilitate the successful management of this condition.
Related news and insights
AbbVie announced that it has submitted applications seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for Skyrizi (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.
AbbVie announced that the New England Journal of Medicine has published 24-week results from the Phase III SELECT-PsA 1 trial evaluating Rinvoq (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
Pfizer Inc. and Eli Lilly and Company announced the outcome of the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 against.